Dr. Winter Discusses Copanlisib in Follicular Lymphoma

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses copanlisib (Aliqopa) in follicular lymphoma.

The intravenous pan-class I PI3K inhibitor copanlisib has shown predominant activity against the PI3K-alpha and -delta isoforms in follicular lymphoma.

Winter says that the category of PI3K inhibitors continues to grow in this disease, and this class of agents will positively add to the armamentarium.